Understanding the Market | CARDIOFLOW-B rose over 4% in the morning and is expected to release its performance at the end of this month, with a projected net loss in the first half of the year decreasing by no less than 83% year-on-year
CARDIOFLOW-B's stock price rose more than 4% in the morning, reaching HKD 1.54, with a transaction volume of HKD 16.2265 million. The company expects a net loss of no more than RMB 10 million in the first half of 2025, a year-on-year decrease of no less than 83%. The main reasons include the growth in overseas sales of the VitaFlow Liberty® product, the commercialization progress of the AnchorMan® system in China, resource allocation optimization, and gains from equity sales. The board of directors will hold a meeting on August 28 to review the interim performance
According to Zhitong Finance APP, CARDIOFLOW-B (02160) rose more than 4% in the morning, and as of the time of publication, it was up 4.05%, priced at HKD 1.54, with a transaction volume of HKD 16.2265 million.
In terms of news, CARDIOFLOW-B plans to hold a board meeting on August 28 to consider and approve its interim results. Previously, CARDIOFLOW-B announced that the group expects to incur a net loss of no more than RMB 10 million in the first half of 2025, a year-on-year decrease of no less than 83%.
The announcement stated that the reduction in net loss is mainly due to: the VitaFlow Liberty® transcatheter aortic valve and retrievable delivery system has achieved sales in more than 20 countries/regions overseas, with revenue from overseas increasing more than twofold year-on-year; the commercialization progress of the AnchorMan® left atrial appendage occluder system and its guiding system in China is steadily advancing, having obtained CE marking and achieved commercialization in Europe during the reporting period, contributing to revenue growth; the group has further improved operational efficiency through continuous optimization of resource allocation and active cost management; and the group's associate company 4C Medical Technologies, Inc. completed its Series D financing, resulting in a decrease in the group's equity stake in 4C Medical, which is recognized as income from the sale of part of its equity
